142 related articles for article (PubMed ID: 35567387)
1. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
[TBL] [Abstract][Full Text] [Related]
2. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
3. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of mammaglobin in salivary duct carcinomas de novo and salivary duct carcinoma ex pleomorphic adenoma.
Soares CD; de Lima Morais TM; Carlos R; Martins MD; de Almeida OP; Mariano FV; Altemani A
Hum Pathol; 2019 Oct; 92():59-66. PubMed ID: 31400353
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
6. Parotid salivary duct carcinoma: a single institution's 20-year experience.
Stodulski D; Mikaszewski B; Majewska H; Kuczkowski J
Eur Arch Otorhinolaryngol; 2019 Jul; 276(7):2031-2038. PubMed ID: 31062093
[TBL] [Abstract][Full Text] [Related]
7. Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma.
Griffith CC; Thompson LD; Assaad A; Purgina BM; Lai C; Bauman JE; Weinreb I; Seethala RR; Chiosea SI
Histopathology; 2014 Dec; 65(6):854-60. PubMed ID: 24804831
[TBL] [Abstract][Full Text] [Related]
8. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of TRKB tyrosine kinase in the two histological types of parotid salivary duct carcinoma with cancer aggressiveness.
Moriwaki K; Ayani Y; Kuwabara H; Terada T; Higashino M; Kawata R
Oral Oncol; 2024 Apr; 151():106751. PubMed ID: 38479153
[TBL] [Abstract][Full Text] [Related]
10. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
11. Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis.
Key S; Chia C; Hasan Z; Sundaresan P; Riffat F; Dwivedi RC
Laryngoscope; 2024 Mar; 134(3):1042-1053. PubMed ID: 37610148
[TBL] [Abstract][Full Text] [Related]
12. Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract.
Agaimy A; Mueller SK; Bishop JA; Chiosea SI
Head Neck Pathol; 2021 Sep; 15(3):769-779. PubMed ID: 33428064
[TBL] [Abstract][Full Text] [Related]
13. Salivary duct carcinoma: A report of 70 FNA cases and review of the literature.
Wakely PE
Cancer Cytopathol; 2022 Aug; 130(8):595-608. PubMed ID: 35255198
[TBL] [Abstract][Full Text] [Related]
14. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
15. Salivary duct carcinoma ex pleomorphic adenoma: analysis of the findings in fine-needle aspiration cytology and histology.
Ersöz C; Cetik F; Aydin O; Cosar EF; Talas DU
Diagn Cytopathol; 1998 Sep; 19(3):201-4. PubMed ID: 9740996
[TBL] [Abstract][Full Text] [Related]
16. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
17. The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma.
Kondo Y; Hirabayashi K; Carreras J; Tsukinoki K; Ota Y; Okami K; Nakamura N
Ann Diagn Pathol; 2021 Feb; 50():151673. PubMed ID: 33248386
[TBL] [Abstract][Full Text] [Related]
18. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
Schmitt NC; Kang H; Sharma A
Oral Oncol; 2017 Nov; 74():40-48. PubMed ID: 29103750
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification.
Simpson RH
Head Neck Pathol; 2013 Jul; 7 Suppl 1(Suppl 1):S48-58. PubMed ID: 23821208
[TBL] [Abstract][Full Text] [Related]
20. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
